Denali Therapeutics Inc. Operating Expenses
Denali Therapeutics Inc. (DNLI) reported Operating Expenses of $137.36 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-05-07
- Denali Therapeutics Inc. operating expenses for the quarter ending 2026-03-31 was $137.36M, a 5.65% decline year-over-year.
- Denali Therapeutics Inc. operating expenses for the quarter ending 2025-12-31 was $137.37M, a 5.79% increase year-over-year.
- Denali Therapeutics Inc. operating expenses for the quarter ending 2025-09-30 was $137.43M, a 11.57% increase year-over-year.
- Denali Therapeutics Inc. operating expenses for the quarter ending 2025-06-30 was $134.96M, a 15.76% increase year-over-year.
- Denali Therapeutics Inc. operating expenses for fiscal 2025 was $555.34M, a 10.65% increase from fiscal 2024.
- Denali Therapeutics Inc. operating expenses for fiscal 2024 was $501.88M, a 4.81% decline from fiscal 2023.
- Denali Therapeutics Inc. operating expenses for fiscal 2023 was $527.23M, a 17.37% increase from fiscal 2022.
- Denali Therapeutics Inc. operating expenses for fiscal 2022 was $449.21M, a 30.43% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-03-31 | $137.36M 10-Q · filed 2026-05-07 | $274.72M derived: sum of 2 quarters · filed 2026-05-07 | $412.16M derived: sum of 3 quarters · filed 2026-05-07 | $547.12M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $137.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $274.80M derived: sum of 2 quarters · filed 2026-02-26 | $409.76M derived: sum of 3 quarters · filed 2026-02-26 | $555.34M 10-K · filed 2026-02-26 |
| 2025-09-30 | $137.43M 10-Q · filed 2025-11-06 | $272.40M derived: sum of 2 quarters · filed 2025-11-06 | $417.98M 10-Q · filed 2025-11-06 | $547.82M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-06-30 | $134.96M 10-Q · filed 2025-08-11 | $280.54M 10-Q · filed 2025-08-11 | $410.39M derived: sum of 3 quarters · filed 2026-05-07 | $533.58M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-03-31 | $145.58M 10-Q · filed 2026-05-07 | $275.43M derived: sum of 2 quarters · filed 2026-05-07 | $398.61M derived: sum of 3 quarters · filed 2026-05-07 | $515.21M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $129.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $253.03M derived: sum of 2 quarters · filed 2026-02-26 | $369.63M derived: sum of 3 quarters · filed 2026-02-26 | $501.88M 10-K · filed 2026-02-26 |
| 2024-09-30 | $123.19M 10-Q · filed 2025-11-06 | $239.78M derived: sum of 2 quarters · filed 2025-11-06 | $372.03M 10-Q · filed 2025-11-06 | $504.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $116.59M 10-Q · filed 2025-08-11 | $248.84M 10-Q · filed 2025-08-11 | $381.42M derived: sum of 3 quarters · filed 2026-02-26 | $496.48M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $132.25M 10-Q · filed 2025-05-06 | $264.82M derived: sum of 2 quarters · filed 2026-02-26 | $379.89M derived: sum of 3 quarters · filed 2026-02-26 | $503.53M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $132.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $247.63M derived: sum of 2 quarters · filed 2026-02-26 | $371.27M derived: sum of 3 quarters · filed 2026-02-26 | $527.23M 10-K · filed 2026-02-26 |
| 2023-09-30 | $115.06M 10-Q · filed 2024-11-06 | $238.70M derived: sum of 2 quarters · filed 2024-11-06 | $394.66M 10-Q · filed 2024-11-06 | $510.29M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $123.64M 10-Q · filed 2024-08-01 | $279.60M 10-Q · filed 2024-08-01 | $395.22M derived: sum of 3 quarters · filed 2025-02-27 | $506.27M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $155.96M 10-Q · filed 2024-05-07 | $271.58M derived: sum of 2 quarters · filed 2025-02-27 | $382.63M derived: sum of 3 quarters · filed 2025-02-27 | $496.52M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $115.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $226.67M derived: sum of 2 quarters · filed 2025-02-27 | $340.57M derived: sum of 3 quarters · filed 2025-02-27 | $449.21M 10-K · filed 2025-02-27 |
| 2022-09-30 | $111.05M 10-Q · filed 2023-11-07 | $224.94M derived: sum of 2 quarters · filed 2023-11-07 | $333.58M 10-Q · filed 2023-11-07 | $423.21M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $113.90M 10-Q · filed 2023-08-08 | $222.53M 10-Q · filed 2023-08-08 | $312.17M derived: sum of 3 quarters · filed 2024-02-28 | $403.05M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $108.64M 10-Q · filed 2023-05-08 | $198.27M derived: sum of 2 quarters · filed 2024-02-28 | $289.15M derived: sum of 3 quarters · filed 2024-02-28 | $373.91M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $89.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $180.51M derived: sum of 2 quarters · filed 2024-02-28 | $265.27M derived: sum of 3 quarters · filed 2024-02-28 | $344.41M 10-K · filed 2024-02-28 |
| 2021-09-30 | $90.88M 10-Q · filed 2022-11-03 | $175.63M derived: sum of 2 quarters · filed 2022-11-03 | $254.78M 10-Q · filed 2022-11-03 | $327.51M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $84.76M 10-Q · filed 2022-08-08 | $163.90M 10-Q · filed 2022-08-08 | $236.64M derived: sum of 3 quarters · filed 2023-02-27 | $306.14M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $79.14M 10-Q · filed 2022-05-05 | $151.88M derived: sum of 2 quarters · filed 2023-02-27 | $221.39M derived: sum of 3 quarters · filed 2023-02-27 | $288.51M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $72.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $142.25M derived: sum of 2 quarters · filed 2023-02-27 | $209.37M derived: sum of 3 quarters · filed 2023-02-27 | $272.94M 10-K · filed 2023-02-27 |
| 2020-09-30 | $69.51M 10-Q · filed 2021-11-04 | $136.63M derived: sum of 2 quarters · filed 2021-11-04 | $200.20M 10-Q · filed 2021-11-04 | $262.63M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $67.12M 10-Q · filed 2021-08-04 | $130.69M 10-Q · filed 2021-08-04 | $193.13M derived: sum of 3 quarters · filed 2022-02-28 | $256.88M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $63.57M 10-Q · filed 2021-05-05 | $126.00M derived: sum of 2 quarters · filed 2022-02-28 | $189.76M derived: sum of 3 quarters · filed 2022-02-28 | $256.72M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $62.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $126.19M derived: sum of 2 quarters · filed 2022-02-28 | $193.15M derived: sum of 3 quarters · filed 2022-02-28 | $239.86M 10-K · filed 2022-02-28 |
| 2019-09-30 | $63.76M 10-Q · filed 2020-11-05 | $130.72M derived: sum of 2 quarters · filed 2020-11-05 | $177.43M 10-Q · filed 2020-11-05 | $228.39M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $66.96M 10-Q · filed 2020-08-07 | $113.67M 10-Q · filed 2020-08-07 | $164.63M derived: sum of 3 quarters · filed 2021-02-26 | $203.79M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $46.71M 10-Q · filed 2020-05-07 | $97.67M derived: sum of 2 quarters · filed 2021-02-26 | $136.83M derived: sum of 3 quarters · filed 2021-02-26 | $195.86M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $50.95M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $90.11M derived: sum of 2 quarters · filed 2021-02-26 | $149.14M derived: sum of 3 quarters · filed 2021-02-26 | $175.53M 10-K · filed 2021-02-26 |
| 2018-09-30 | $39.16M 10-Q · filed 2019-11-06 | $98.19M derived: sum of 2 quarters · filed 2019-11-06 | $124.58M 10-Q · filed 2019-11-06 | $148.12M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $59.03M 10-Q · filed 2019-08-06 | $85.42M 10-Q · filed 2019-08-06 | $108.96M derived: sum of 3 quarters · filed 2020-02-27 | $131.25M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $26.39M 10-Q · filed 2019-05-08 | $49.93M derived: sum of 2 quarters · filed 2020-02-27 | $72.22M derived: sum of 3 quarters · filed 2020-02-27 | $94.78M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $23.54M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $45.83M derived: sum of 2 quarters · filed 2020-02-27 | $68.40M derived: sum of 3 quarters · filed 2020-02-27 | $90.14M 10-K · filed 2020-02-27 |
| 2017-09-30 | $22.29M 10-Q · filed 2018-11-08 | $44.86M derived: sum of 2 quarters · filed 2018-11-08 | $66.60M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $22.57M 10-Q · filed 2018-08-09 | $44.31M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $21.74M 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $87.43M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |